- Exchange: NASDAQ GM
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
Snapshot for Arqule Inc (ARQL)
| Open: | 2.7800 | Day's Range: | 2.6800 - 2.8300 | Volume: | 174,462 |
|---|---|---|---|---|---|
| Previous Close: | 2.7100 | 52wk Range: | 1.9800 - 6.9800 | 1-Yr Rtn: | -53.20% |
Key Statistics for ARQL
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. SPX | - |
| Earnings Per Share (USD) (ttm) | -0.2000 |
| Est. EPS (USD) (12/2013) | -0.4500 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 169.71 |
| Shares Outstanding (M) | 62.62 |
| 30 Day Average Volume | 272,121 |
| Price/Book (mrq) | 2.2147 |
| Price/Sale (ttm) | 4.9868 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/02/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for ARQL
Company Profile & Key Executives for ARQL
ArQule Inc. develops cancer therapeutics based on its proprietary Activated Checkpoint Therapy platform. The Company's platform is designed to produce small molecule compounds that selectively kill cancer cells while leaving normal cells unharmed. ArQule's products are intended to be effective against multiple types of cancer.
| Paolo PucciChief Executive Officer | Peter S LawrencePresident/COO/Secy/Gen Cnsl |
| Brian SchwartzSenior VP/Chief Medical Ofcr | Thomas C K ChanSenior VP/Chf Scientific Ofcr |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
ARQL News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page